Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099541 · ClinicalTrials.gov registry record · Phase 4
Non-small Cell Lung Cancer Registry
A Phase 4 study of Non-Small Cell Lung Cancer and Pleural Effusion, Malignant, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT00099541: Completed Phase 4 study of Non-Small Cell Lung Cancer and Pleural Effusion, Malignant, sponsored by Novartis Pharmaceuticals.
NCT00099541 is a Phase 4 study of Non-Small Cell Lung Cancer and Pleural Effusion, Malignant that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 300 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00099541, a Phase 4 study of Non-Small Cell Lung Cancer and Pleural Effusion, Malignant, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage IIIB/IV non-small cell lung cancer patients that has spread to the bones. The objective of Group 2 is to see if a blood test can be used to predict when cancer-related bone lesions develop. This trial is seeking patients 18 years or older that have been diagnosed with Stage IIIB or Stage IV non-small cell lung cancer that cannot be treated by surgery.
Conditions Studied
Interventions
- DRUG zoledronic acid
Study Locations (20)
California
- Pacific Cancer Medical Center Inc. - Anaheim
- Bay Area Cancer Research Group - Concord
- Fresno Hem/Onc Medical Group - Fresno
- Beaver Med Group - Highland
- Redwood Regional Medical Group - Santa Rosa
- Stockton Hem. Onc. - Stockton
Florida
- Gainesville Hematology Oncology Associates - Gainesville
- Baptist Cancer Institute - Jacksonville
- Center for Cancer Care & Research - Lakeland
- Lake Heart & Cancer Center - Leesburg
- Melbourne Internal Medicine Assoc (MIMA) Century Research - Melbourne
- Pasco Pinellas Cancer Center - New Port Richey
Colorado
- Rocky Mountain Cancer Centers - Denver
- Front Range Cancer Specialists - Fort Collins
- Greeley Medical Clinic - Greeley
- Western Hematology/Oncology - Lakewood
Alabama
- Birmingham Hematology and Oncology Associates - Birmingham
Arkansas
- Hembree Cancer Center-St. Edward Mercy Medical Center - Fort Smith
Connecticut
- Hematology Oncology PC - Stamford
Delaware
- Christiana Care Health Services - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
What the finished NCT00099541 record still lists
NCT00099541 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which zoledronic acid is the first listed.
NCT00099541 names 20 study sites across 7 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00099541 about?
NCT00099541 is a clinical study titled "Non-small Cell Lung Cancer Registry". This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage IIIB/IV non-small cell lung cancer patients that has spread to the bones. The objective of Group 2 is to see if a blood tes...
What is the current status of trial NCT00099541?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2004-11. Estimated completion is 2007-11.
What conditions does trial NCT00099541 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Pleural Effusion, Malignant.
What interventions are being tested in trial NCT00099541?
The interventions under investigation include: zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00099541?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00099541 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00099541's enrollment target sits among peer trials
300 124th of 454 higher than 329 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Lorlatinib Continuation Study
ACTIVE NOT RECRUITING · Phase 4
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
- NCT01266577 · 300 participants · NA
Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia